At the end of treatment-free intervals up to 80 days, patients with atopic dermatitis treated with tapinarof maintained low disease level.

Just like humans, dogs can suffer from seasonal allergies triggered by environmental factors such as pollen, mold, and dust ...

Has your dog been licking and chewing at their paws a lot lately? Allergies might be to blame. Here's what you should know to ...

1 “Many patients with moderate to severe atopic dermatitis struggle with chronic, life-disrupting symptoms,” said Jay Bradner, M.D., executive vice president of Research and Development at Amgen.

Amgen and Kyowa Kirin’s anti-OX40 antibody rocatinlimab vindicated itself this weekend, with new Phase III data pointing to its strong efficacy in moderate to severe atopic dermatitis. These findings ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of eczema, known as atopic dermatitis, is characterized by persistent itching ...

in moderate to severe atopic dermatitis (AD). The companies noted that the IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary ...

in moderate to severe atopic dermatitis (AD). The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving ...

The open-label portion also enrolled patients from a four-week pharmacokinetics study and patients 2 to 17 years of age with either mild, moderate, or severe atopic dermatitis that did not meet ...

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved complete or near complete skin clearance at three years on a single monthly ...

A new Phase-3b study has found that lebrikizumab (EBGLYSS; Lilly), a monoclonal antibody targeting interleukin-13, improves itch, sleep interference, and skin pain in patients with moderate-to-severe ...